套细胞淋巴瘤的靶向治疗

 套细胞淋巴瘤（MCL）是最令人失望的疾病之一，因其具有侵袭性非霍奇金淋巴瘤（NHL）及惰性NHL的不良特征，前者进展迅速，后者难以治愈，且缺乏最佳治疗选择。临床研究证实利妥昔单抗单用或与化疗联合方案治疗MCL有效。波替单抗治疗MCL也有效，在联合方案中尚需进一步研究。哺乳动物雷帕霉素抑制剂与放射免疫治疗MCL代表一种新的治疗方法，值得进一步研究。

Targeted therapy of mantle cell lymphoma

Mantle cell lymphoma(MCL) is one of the most frustrating diseases because it exhibits the worst features of both aggressive non-Hodgkin Lymphoma(NHL) and indolent NHL. It develops rapidly like the former, and it is incurable and lacks of better therapeutic options like the latter. Clinical researchs confirm the activity of rituximab as a single agent and combination regimens (R-Chemo) in the treatment of MCL. Bortezomab is also active in treating patients with MCL and requires further study in combination regiments. The usages of mTOR inhibitor and radioimmunotherapy represents a novel therapeutic approaches in the treatment of MCL. It is also deserved to study.